Last updated: July 18, 2026
Cardene in 0.86% Sodium Chloride in Plastic Container is an IV nicardipine hydrochloride product using a premixed saline vehicle in a plastic container. For investment-screening and risk modeling, the commercial and IP profile hinges on (1) FDA exclusivity attached to the specific NDA/NDC strength and container configuration, (2) the Orange Book patent set for that exact listed product, and (3) whether later-filed generics can rely on FDA-approved labeling and manufacturing design-arounds that stay clear of formulation, process, and container-related patents.
This analysis cannot be completed to a decision-grade standard because the required dataset elements (the specific FDA application identifiers, Orange Book patent numbers/listings by drug strength and container configuration, and any current ANDA/Para IV litigation records tied to this exact product) are not provided.
What patents protect Cardene in 0.86% Sodium Chloride in Plastic Container?
No complete patent estate mapping can be produced without the specific Orange Book listing(s) and associated application number(s) for the plastic-container presentation.
Which patent categories usually matter for IV nicardipine premix products?
For premixed parenteral products, the relevant patent buckets typically include:
- Composition/premix formulation (drug-to-saline concentration, pH targets, excipient system)
- Sterile manufacturing/process parameters (sterilization, filtration, hold times)
- Container-closure system (compatibility, extractables/leachables, adsorption)
- Method-of-use (indication-specific dosing or patient populations)
- Stability/expiration dating and shelf-life extensions
A decision-grade “how many patents” and “what do they claim” breakdown requires the actual listed patent numbers and claim scope from the Orange Book record tied to the specific NDC/container.
When does Cardene lose exclusivity for the plastic-container IV presentation?
A precise exclusivity timeline (non-patent exclusivity and patent expirations) requires:
- The NDA reference for this presentation
- Any pediatric exclusivity, 5-year exclusivity, or 3-year exclusivity grants tied to the relevant approval
- Patent expiration dates for the specific Orange Book entries listing this exact dosage form/container
No timeline can be stated accurately without those identifiers.
What is the Orange Book status of Cardene in 0.86% Sodium Chloride in Plastic Container?
Orange Book status is presentation-specific. “Cardene” products often vary by concentration, route, and formulation vehicle. Without the exact Orange Book listing entries (NDA number and strength-specific patent list), the status (patents expiring, expiring soon, listed for NDA vs. supplement, and whether there are multiple competing listed products) cannot be mapped.
How many patents cover this nicardipine IV saline premix product, and what are their expiration dates?
A quantified patent landscape requires the Orange Book patent list for:
- Nicardipine HCl IV concentration(s) included under “0.86% Sodium Chloride”
- Plastic container SKU configuration(s) that correspond to the market-facing product
- Associated formulation/process/patent family membership and jurisdiction coverage
Without those patent listings, any count or expiration-date table would be non-actionable.
Are there Paragraph IV ANDA challenges for this nicardipine IV premix?
ANDA/Para IV activity is record-specific to the NDA and listed product (including container and strength). A defensible competitive risk screen requires:
- Published ANDA submissions referencing the same NDA
- Patent certifications (Paragraph I/II/III/IV) per listed patent
- Any litigation docket entries and settlement terms
No litigation mapping can be produced from the information given.
What generic entry risks exist for Cardene IV nicardipine in plastic containers?
Generic entry risk depends on:
- Whether the key Orange Book patents are composition/formulation, process, or container-related
- Whether generic applicants need bioequivalence waivers or face in-use stability and compatibility constraints
- Whether design-around is feasible without changing key quality attributes that drive label acceptance
A decision-grade risk score requires the actual patent claim types and expiration schedule for the exact product listing.
How does Cardene in saline compare with other IV nicardipine formulations on IP barriers?
A fair comparison requires:
- Competitor products (including syringe/bag formats, strengths, premix vs. reconstitution pathways)
- Their Orange Book patent estates
- Any known substitutions in hospital formularies
Without competitor-specific Orange Book data, comparison cannot be made.
What FDA pathway status affects time-to-generic for this product?
The regulatory pathway (505(b)(1), 505(j) ANDA, or 505(b)(2) for line extensions) affects exclusivity and the ability to support abbreviated approvals. This product-level pathway cannot be confirmed without the NDA/APPL identifiers tied to the specific presentation.
What patent litigation affects nicardipine IV premix generics?
Litigation affects exclusivity “real-world timing” through:
- 30-month stay (automatic under certain Para IV filings)
- Injunction/earlier launch risk
- Settlement-driven agreed entry dates
A litigation scan requires dockets and the patent list for the specific NDA.
Commercial fundamentals: is Cardene IV nicardipine premix investable?
Investment fundamentals for hospital IV antihypertensive premixes typically track:
- Supply continuity and manufacturing resiliency (sterile parenterals)
- Hospital procurement cycle and formulary stability
- Replacement risk by alternative brands or generics post-launch
- Contract exposure (group purchasing organizations)
However, cash-flow and revenue exposure modeling for this exact product requires at least one of the following: NDC-level sales history, wholesaler channel data, or publicly available company segment disclosures tied to this SKU. None is provided.
Key IP-driven investment scenario framework (what to model)
Even without specific Orange Book data, a structure for scenario modeling is:
- Base case: No Para IV challenges; patents that block generic entry expire on schedule; generic entry only after last listed patent/any exclusivity.
- Upside: Early resolution of patent disputes or narrow claim scope that enables a design-around; faster-than-scheduled generic availability compresses branded margin but may improve liquidity if you hold supplier manufacturing leverage.
- Downside: Broad formulation/process/container patents remain unchallenged; entry is blocked for longer; branded pricing power persists but revenue risk concentrates in hospital procurement and supply events.
These scenarios still require the actual patent and litigation dataset to quantify probability and timing.
Key Takeaways
- A complete investment-grade patent and exclusivity assessment for Cardene in 0.86% Sodium Chloride in Plastic Container requires Orange Book listing-level identifiers and patent numbers tied to the specific presentation.
- Competitive and litigation risk for generic entry is presentation-specific and cannot be quantified without ANDA/Para IV records tied to the same NDA/NDC.
- Commercial fundamentals are SKU-level for sterile IV products; without product-level sales and channel exposure, the scenario set cannot be translated into revenue-at-risk or margin-at-risk.
FAQs
- What Orange Book patents typically block generic nicardipine IV premix products?
- How do plastic container-closure patents affect generic approval for IV saline premixes?
- Do Para IV ANDA filings for nicardipine depend on container and strength-specific listings?
- What exclusivity types (pediatric, 3-year, 5-year) most often extend IV generic entry timing?
- How should investors model revenue risk for sterile antihypertensive IV injectables around last patent expiry?
References
(No sources cited because specific FDA Orange Book, exclusivity, litigation, and patent listing data for this exact presentation were not provided.)
